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Background: Correct characterization of focal solid hepatic lesions has always been a challenge and is of great
diagnostic and therapeutic relevance. The purpose of this study was to determine the added value of hepatobiliary
phase images in Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) for differentiating focal solid
hepatic lesions.
Methods: In this retrospective trial 84 consecutive patients underwent Gd-EOB-DTPA-enhanced MR examinations.
MRI was conducted for 64 patients with malignant focal hepatic lesions (34 hepatocellular carcinoma (HCC),
30 metastases) and for 20 patients with benign hepatic lesions (14 focal nodular hyperplasia (FNH), 3 adenoma,
3 hemangioma). Five radiologists independently reviewed three sets of MR images by means of a 5-point
confidence scale from score 1 (definitely benign) to score 5 (definitely malignant): set 1: unenhanced images; set 2:
unenhanced and Gd-EOB-DTPA-enhanced dynamic images; set 3: hepatobiliary phase images in addition to set 2.
Accuracy was assessed by the alternative free-response receiver operating characteristic curve (Az) and the index
of diagnostic performance was calculated.
Results: Diagnostic accuracy was significantly improved by the addition of Gd-EOB-DTPA-enhanced dynamic
images: Az in set 1 was 0.708 and 0.833 in set 2 (P = 0.0002). The addition of hepatobiliary phase images
increased the Az value to 0.941 in set 3 (set 3 vs set 2, P < 0.0001; set 3 vs set 1, P < 0.0001). The index of diagnostic
performance was lowest in set 1 (45%), improved in set 2 (71%), and highest in set 3 (94%).
Conclusions: Hepatobiliary phase images obtained after Gd-EOB-DTPA-enhanced dynamic MRI improve the
differentiation of focal solid hepatic lesions.
Keywords: Magnetic resonance imaging, Focal hepatic lesions, Gd-EOB-DTPA-enhanced MR imaging, Hepatobiliary,
Diagnostic performance, CharacterizationBackground
Focal solid hepatic lesions include primary liver malig-
nancies, metastases, and benign tumor-like lesions. The
detection and accurate characterization of such lesions
is of high clinical importance for surgical interventions
and minimally invasive tumor therapies. MR imaging
(MRI) of the liver with an extracellular contrast medium,
such as gadopentetate dimeglumine (Gd-DTPA) and* Correspondence: michael.haimerl@ukr.de
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reproduction in any medium, provided the orparticularly liver-specific contrast agents, has been
shown to increase the detection rate and the diagnostic
accuracy of focal solid hepatic lesions in comparison to
other noninvasive modalities including ultrasonography
(US) and computed tomography (CT) [1-4]. Over the
past 10 years, several liver-specific MRI contrast media
have been developed, for example, superparamagnetic
iron oxide particles targeting Kupffer cells and gadobe-
nate dimeglumine (Gd-BOPTA) or mangafodipir triso-
dium (Mn-DPDP), which are taken up by hepatocytes.
These contrast agents have been investigated in clinical
trials with the objective of increasing the performance ofl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tobiliary contrast agent Gadolinium ethoxybenzyl diethy-
lenetriaminepentaacetic acid (Gd-EOB-DTPA, gadoxetic
acid disodium, Primovist, Schering, Berlin, Germany)
has been introduced for hepatic MRI examinations.
Gd-EOB-DTPA is a hydrophilic, paramagnetic, highly
water-soluble, and therefore bolus-injectable Gd-DTPA
derivate for T1-weighted MRI that allows the evaluation
of delayed hepatocyte uptake and biliary excretion [8,9].
Approximately 50% of the injected dose is taken up by
functioning hepatocytes and excreted in bile compared to
a hepatocellular uptake rate of 3% to 5% for gadobenate
dimeglumine [10].
In principle, injected Gd-EOB-DTPA accumulates in
hepatocytes during the hepatobiliary phase. Consecutive
normal areas of the liver ─ in contrast to malignant focal
hepatic lesions, such as metastases ─ exhibit T1-shorten-
ing. Gd-EOB-DTPA produces both dynamic perfusion
and liver-specific hepatobiliary MR images, thus combin-
ing the properties of an extracellular fluid contrast agent
and a hepatobiliary agent [11,12].
Recent studies showed that Gd-EOB-DTPA-enhanced
hepatobiliary phase MR images can help differentiating
hepatocellular carcinoma (HCC) from arterial enhancing
pseudolesions and that combined reading with pre-
contrast and Gd-EOB-DTPA-enhanced MR images may
improve the diagnostic performance for the diagnosis of
HCCs [13-15].
The purpose of this trial was to determine the value of
hepatobiliary phase post-contrast images in gadoxetic
acid-enhanced MRI in addition to unenhanced and
contrast-enhanced dynamic MRI for obtaining the high-
est possible accuracy in characterizing such lesions in
the clinical routine of a university hospital.
Methods
Patients
The Ethics Committee deemed approval of this retro-
spective trial unnecessary. Between January 2009 and
September 2010, 194 consecutive patients with focal
hepatic lesions diagnosed using US or CT examination
underwent hepatic gadoxetic acid disodium-enhanced
MRI to confirm or rule out malignancy. Exclusion
criteria were portal vein thrombosis, as well as obvious
malignancies, such as disseminated liver metastases,
peritoneal carcinomatosis, or local lymph node metasta-
ses. Other exclusion criteria were history of chemother-
apy including transcatheter arterial chemoembolization
(TACE), history of thermal ablation, presence of hemosi-
derosis or hemochromatosis. Eighty-four patients, i.e. 54
men (mean age: 66.7; age range: 43 to 86 years) and 30
women (mean age: 53.2; age range: 21 to 83 years), met
the inclusion criteria of this trial. Figure 1 summarizes
the patient flowchart.Standard of reference
Diagnosis of HCC was either confirmed by histology,
based on surgical findings (n = 5) or on results of percu-
taneous biopsies (n = 24), or obtained from patholo-
gically elevated α-fetoprotein (AFP) values (>196 ng/ml)
(n = 5). The diameter of the 34 HCCs ranged from
0.8 cm to 14 cm. Diagnosis of hepatic metastases was
based on resection (n = 8), percutaneous biopsy (n = 8),
or typical image analysis if the primary tumor was
known (n = 14). Twenty lesions were considered benign
(focal nodular hyperplasia (FNH) n = 14, hemangioma
n = 3, adenoma n = 3) because of the absence of interval
changes in the follow-up CT or MR images for more than
6 months without treatment. Figure 1 summarizes how
diagnosis of hepatic lesions was confirmed.
MR Imaging
Gadoxetic acid-enhanced MRI was conducted for all
patients by means of a 1.5-T system (Magnetom Sym-
phony, Siemens, Erlangen, Germany) with the manufac-
turer’s body and spine array coils. The entire liver was
imaged in the transverse plane.
First, we obtained respiratory-triggered single-shot
T2-weighted turbo spin-echo images (repetition time
(TR)/echo time (TE): 1000/85; flip angle: 150°; slice
thickness: 6 mm; matrix: 180 × 320) followed by two
different breath-hold fast-spoiled gradient-echo images, i.
e. T1-weighted in-phase (repetition time (TR)/echo time
(TE): 87/4.8; flip angle: 60°; slice thickness: 6 mm; matrix:
154 × 320) and T1-weighted out-of-phase images (repe-
tition time (TR)/echo time (TE): 100/2.7; flip angle: 70°;
slice thickness: 6 mm; matrix: 154 × 320).
Then, we conducted a three-dimensional T1-weighted
gradient-echo sequence (repetition time (TR)/echo time
(TE): 4.0/1.5; flip angle: 10°; slice thickness: 6 mm;
matrix: 174 × 320) using the fat suppression technique.
After the administration of 10 ml Gd-EOB-DTPA
(Primovist; Bayer Schering, Berlin, Germany), the same
sequence was repeated with dynamic contrast-enhanced
MRI. The contrast material was injected with a power
injector as a bolus at a rate of 2 mL/s via a 22-gauge
intravenous cubital line flushed with 15 mL of saline.
Dynamic contrast-enhanced MRI was initiated after the
start of the bolus injection to obtain multi-phasic images
(arterial, portal, and equilibrium phases). Additionally,
hepatobiliary phase images were obtained after 20 min
using the same dynamic contrast-enhanced MR se-
quence. Also, respiratory-triggered T2-weighted turbo
spin-echo images with fat suppression (repetition time
(TR)/echo time (TE): 2220/79; flip angle: 140°; slice
thickness: 6 mm; matrix: 320 × 320) and respiratory-
triggered diffusion-weighted images (repetition time
(TR)/echo time (TE): 1900/72; slice thickness: 6 mm;
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Figure 1 Flowchart of patients and lesions included in this trial. 194 patients underwent Gd-EOB-DTPA-enhanced MRI of the liver. 110
patients were excluded, mainly because of missing follow-up examinations, and 84 consecutive patients were included. Malignant lesions (n = 64)
were proven by histology (n = 45), or diagnosis was either based on AFP > 196 ng/ml (n = 5) or knowledge of the primary tumor in case of
metastases (n = 14). Benign lesions (n = 20) showed no change on follow-up examinations for more than 6 months.
Haimerl et al. BMC Medical Imaging 2013, 13:41 Page 3 of 8
http://www.biomedcentral.com/1471-2342/13/41and the hepatobiliary phase as part of the routine liver
MRI protocol (Table 1).
Imaging analysis
Five radiologists (with 1, 5, 6, 10, and 16 years of experi-
ence in abdominal imaging respectively) independently
reviewed 3 sets of MR images in random order: set 1,Table 1 MR imaging parameter
Parameter T2-weighted imaging unenhanced T
Sequence Fast spin-echo
Respiratory-triggered Yes
Matrix 180 × 320
Section thickness (mm) 6
Flip angle (degrees) 150
Field of view 285 × 380
Repetition time (ms) 1000
Echo time (ms) 85
Acquisition time >79 sunenhanced (precontrast T1- and T2-weighted) images;
set 2, unenhanced and gadoxetic acid-enhanced dynamic
images (arterial, portal, and equilibrium phases); set 3,
unenhanced, gadoxetic acid-enhanced dynamic images
(arterial, portal, and equilibrium phases) and hepatobili-
ary phase images 20 min after Gd-EOB-DTPA bolus
injection. The 5 observers were blinded to laboratory1-weighted imaging unenhanced Contrast-enhanced imaging
Gradient-echo, FLASH Gradient-echo, FLASH
No No
174 × 320 174 × 320
6 6
10 10
344 × 380 344 × 380
4.0 4.0
1.5 1.5
17 s 17 s
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modalities, and final diagnoses. The interval between the
reviews of the 3 sets of images was at least 3 weeks.
Each observer used a 5-point confidence rating scale
for the respective set to evaluate each lesion as follows:
score 1: definitely benign, score 2: preferentially benign,
score 3: unclear; score 4: preferentially malignant; score
5: definitely malignant.
Statistical analysis
Statistical analyses were done with a commercially
available software program (MedCalc, version 12.1.4,
MedCalc Software, Mariakerke, Belgium). The means of
age between men and women were compared with the
Mann–Whitney U-test. A receiver operating characteris-
tic analysis with the maximum likelihood estimation
program (ROCKIT DBMMRMC 2.2 B3, C.E. Metz,
University of Chicago, Chicago, Ill) was conducted to
show the diagnostic performance with dynamic gadoxe-
tic acid-enhanced MRI. For each observer, diagnostic
accuracy (area under the alternative free-response re-
ceiver operating characteristic curve (Az)) was calculated
and compared.
The index of diagnostic performance was determined
as the sum of lesions correctly rated as definitely benign
(1) or preferentially benign (2) among benign lesions
and as preferentially malignant (4) or definitely malig-
nant (5) among malignant lesions.
Results
Az values for each observer are shown in Table 2. For all
5 observers, Az values for combined unenhanced and
gadoxetic acid-enhanced dynamic and hepatobiliary
phase images (set 3; observer 1: 0.890; observer 2: 0.923;
observer 3: 0.934; observer 4: 0.975; observer 5: 0.984
were significantly higher than those for unenhanced
images (set 1; observer 1: 0.677 (P = 0.002); observer 2:
0.695 (P = 0.002); observer 3: 0.634 (P < 0.0001); observer
4: 0.725 (P = 0.0001); observer 5: 0.810 (P = 0.002)). Four
out of the 5 observers achieved higher Az values for
combined unenhanced and gadoxetic acid-enhanced
dynamic images (set 2; observer 1: 0.659; observer 2:Table 2 Az values for characterization of focal solid
hepatic lesions for each observer (Sets are defined in the
Methods section)
Observer Set 1 Set 2 Set 3 p value
Set 1 vs. Set 2
p value
Set 2 vs. Set 3
Observer 1 0.677 0.659 0.890 0.835 0.001
Observer 2 0.695 0.837 0.923 0.112 0.081
Observer 3 0.634 0.789 0.934 0.047 0.009
Observer 4 0.725 0.892 0.975 0.014 0.004
Observer 5 0.810 0.989 0.984 0.0004 0.7480.837, observer 3: 0.789; observer 4: 0.892; observer 5:
0.989) than for unenhanced images (set 1); for one
observer, values were not statistically significant.
Furthermore, 4 out of 5 observers got higher Az values for
additional hepatobiliary phase images, and 3 out of these
4 observers achieved a significant increase (observer 1:
P = 0.001; observer 3: P = 0.009; observer 4: P = 0.004;).
The mean Az value of all observers in set 2 (mean
Az = 0.833; 95% confidence interval (CI) = 0.788-0.863)
was significantly higher than in set 1 (mean Az = 0.708;
95% CI = 0.655-0.745; P = 0.0002). The mean Az value of
all observers in set 3 (mean Az = 0.941; 95% CI = 0.908-
0.958) was significantly higher than in set 2 (P < 0.0001)
(Figure 2 and Table 3).
The index of diagnostic performance regarding the
differentiation between benign and malignant lesions
was 45% in unenhanced T1- and T2-weighted images
(Set 1). Accuracy improved in unenhanced and gado-
xetic acid-enhanced dynamic images (Set 2; 71%) and
was highest in set 3 with additional hepatobiliary phase
images (94%).
With unenhanced T1- and T2-weighted images (set 1),
37.9% of the lesions were rated as unclear (score 3).
With dynamic phase images (set 2), this rate could be
lowered to 18.1%. The combination of unenhanced im-
ages, dynamic images, and additional hepatobiliary phase
images (set 3) further decreased this rate to 6.7%.
A representative image of each benign and malignant
focal solid hepatic lesion is shown in Figure 3. Imaging
findings of respective benign and malignant lesions are
shown in Table 4.
Discussion
The early detection and characterization of hepatic lesions
has become increasingly important because surgical andFigure 2 ROC analysis of each set for all observers. Areas under
the curve were 0.708 for set 1, 0.833 for set 2, and 0.941 for set 3.
Table 3 Diagnostic performance of all observers (mean Az) for imaging sets
Set 1 Set 2 Set 3 p value set 1 vs. set 2 p value set 2 vs. set 3
Mean AZ 0.708 0.833 0.941 0.0002 <0.0001
95% CI 0.655-0.745 0.788-0.863 0.908-0.958
Haimerl et al. BMC Medical Imaging 2013, 13:41 Page 5 of 8
http://www.biomedcentral.com/1471-2342/13/41minimally invasive interventional techniques may cure or
at least improve diagnosis [16].
Several trials have proven that contrast-enhanced MRI
is more sensitive in the detection of hepatic metastases
and HCC than dynamic contrast-enhanced CT, probably
because of the superior delineation of the contrast
between lesion and liver and a more subtle depiction of
the different tissue properties [3,11,17,18].
Therefore, numerous magnetic resonance contrast
agents are available to facilitate the detection and
characterization of hepatic lesions in MRI. Among these
agents, Gd-EOB-DTPA has become increasingly more
important because this contrast medium is able to
create both dynamic phase images as well as liver
specific (hepatocyte phase) MR images within the same
examination [19].
In non-cirrhotic patients, the liver-specific hepatocyte
phase can be scanned as early as 10 min after the injec-
tion of the contrast medium; however, many patients
undergoing liver MRI suffer from liver cirrhosis that
results in delayed Gd-EOB-DTPA hepatocyte uptake.
Thus, a 20 min delay appears to be more appropriate
[20]. Several trials have shown the best liver-to-lesion
contrast 20 min after the injection of Gd-EOB-DTPA
without any significant improvement in hepatobiliary
phase images later than 20 min post-injectionem [12,21].
In early dynamic images, hypervascular benign hepatic
lesions (e.g. hemangioma, FNH, adenoma) have to be
distinguished from hypervascular metastases and HCCs
that show arterial enhancement. Thus, if extracellularFigure 3 Hepatobiliary phase images of benign and malignant focal s
gradient-echo sequence (TR/TE: 4.0/1.5; flip angle: 10°; slice thickness: 6 mm
phase: white arrows depict (A) hyperintense FNHs with central scar, (B) hy
HCC and (E) hypointense metastasis.contrast agents are used, HCCs frequently appear isoin-
tense on equilibrium phase images, which might impede
correct differentiation [22,23]. In the majority of cases in
our trial, however, the use of gadoxetic acid-enhanced
MR images led to rapid and strong enhancement of the
liver parenchyma that showed arterial enhancement and
clear wash-out during the late dynamic images, which
increased diagnostic accuracy. However, enhancement
patterns of HCCs on dynamic phase images and hepa-
tobiliary phase images are dependent from type and
progression of hepatocarcinogenesis. HCCs with atypical
enhancement patterns in terms of missing arterial hyper-
vascularity and consecutive missing wash-out pattern in
delayed phase are shown in majority of cases to have a
lower histologic grade, lower tumor aggressiveness, and
a consecutive better clinical outcome [24]. However,
atypical HCCs carry the risk to be overlooked in
dynamic phase images and Gd-EOB-DTPA-enhanced
hepatobiliary phase images have been shown to improve
both detection and characterization of those lesions [15].
Only recently the malignant potential of hypointense
lesions detected in the hepatobiliary phase of Gd-EOB-
DTPA-enhanced MRI has been shown emphasizing its
clinical benefit [25].
MRI is widely used for the differential diagnosis of
benign hepatic lesions, such as FNH and hepatocellular
adenoma (HCA). Both types of lesions are managed
rather differently: whereas FNH do usually not require
resection and are treated conservatively, HCA are
commonly surgically removed to avoid serious clinicalolid hepatic lesions. A-E, Transverse 3D fat-suppressed T1-weighted
) obtained 20 min after Gd-EOB-DTPA administration in hepatobiliary
pointense adenoma, (C) hypointense hemangioma, (D) hypointense












Hyperintense 23 2 14 0 3
Isointense 8 12 0 0 0
Hypointense 3 16 0 3 0
Portal venous phase imaging
Hyperintense 7 0 7 0 2
Isointense 12 9 7 0 1
Hypointense 15 21 0 3 0
Equilibrium phase imaging
Hyperintense 5 0 7 0 2
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Hepatobiliary phase imaging
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hypervascular lesions on enhanced dynamic images, which
leads to diagnostic problems in differential diagnosis.
However, it could be shown recently that Gd-EOB-DTPA-
enhanced hepatobiliary phase MRI facilitates the accurate
differentiation between FNH and HCA: whereas FNH
lesions appeared hyperintens in comparison to the adja-
cent liver parenchyma, adenoma were markedly hypoin-
tens in hepatobiliary phase images [27].
Furthermore, other trials have shown that Gd-EOB-
DTPA-enhanced hepatobiliary phase MRI is superior to
CT or standard gadolinium chelates, particularly in the
differential diagnosis of hypervascular lesions and in the
detection of small metastases, because detection rates
and correct characterization have increased [8,19,28].
The results of our trial show the significant advantage
of Gd-EOB-DTPA-enhanced MRI in evaluating hepatic
tumor specimens:
The diagnostic performance of 4 out of 5 observers was
better with early dynamic phase images than with plain
T1- and T2-weighted images, whereas the diagnostic per-
formance of 1 observer did not improve after the addition
of dynamic images (Az set 1: 0.677; Az set 2: 0.659).
However, the additional information on tissue struc-
ture gained from Gd-EOB-DTPA-enhanced MRI during
the hepatobiliary phase is of high importance for the
interpretation of focal solid hepatic lesions, thus this tool
still aids diagnostic accuracy. In our trial, the Az value
could be increased with additional hepatobiliary phase
images for 4 out of 5 observers. However, the observerwhose performance did not improve with hepatobiliary
phase images (observer 5) had already shown the highest
diagnostic performance with Gd-EOB-DTPA-enhanced
dynamic images (Az Set 2: 0.989). Regarding the fact
that observer 5 had 16 years of experience in abdominal
imaging and observer 1 was the most inexperienced of
the 5 observers, the added value of Gd-EOB-DTPA-en-
hanced hepatobiliary phase images seems to be most
apparent for radiologists who are not only specialized in
abdominal MRI. Therefore, Gd-EOB-DTPA-enhanced
dynamic imaging might be a crucial tool for quotidian
use in a university hospital, where most radiologists are
expected to run several imaging-units simultaneously.
The index of diagnostic performance showing a mean
overall accuracy of the respective set for all 5 observers
was significantly higher with dynamic images (71%) com-
pared to T1- and T2- weighted images (45%) and highest
with the addition of hepatobiliary phase images in set 3
(94%). This increase was very likely caused by the constant
decrease of score 3, meaning “unclear” in subsequent sets
ranging from 38% in set 1 to 7% in set 3.
Our trial has several limitations. First, we did not
conduct a needle biopsy of every hepatic nodule. The
majority of malignant lesions was either proven by
histology or based on surgical findings or on results of
percutaneous biopsy. There was only a low number of
benign lesions and benign lesions were not histologically
confirmed but regarded as benign if they remained un-
changed at the follow-up examinations for more than
6 months without treatment in combination with typical
imaging findings in previous examinations. Second, Gd-
EOB-DTPA-enhanced MRI was conducted regardless of
the liver function; delayed hepatocyte uptake concurs
with diminished liver function, which might have influ-
enced the diagnostic performance, particularly in case of
HCC on cirrhosis. Consequently, it may be difficult to
clearly define the value of contrast-enhanced dynamic
and hepatobiliary phase images.
Conclusion
The results of our trial support the conclusion that Gd-
EOB-DTPA contrast-enhanced hepatobiliary phase MRI
has an additional diagnostic value for the differential
diagnosis of focal solid hepatic lesions in clinical routine
and therefore the potential to improve diagnostic per-
formance; notably, the added diagnostic value of Gd-
EOB-DTPA-enhanced hepatobiliary phase MRI became
more apparent particularly for radiologists with less ex-
perience in liver MRI.
In summary, Gd-EOB-DTPA-enhanced MRI is a use-
ful tool for assessing the possible malignancy of focal
solid hepatic lesions in clinical routine and therefore for
the staging of malignant disease prior to surgery or per-
cutaneous interventional therapies.
Haimerl et al. BMC Medical Imaging 2013, 13:41 Page 7 of 8
http://www.biomedcentral.com/1471-2342/13/41Abbreviations
AFP: α-fetoprotein; Az: Area under the alternative free-response receiver oper-
ating characteristic curve; CT: Computed tomography; FNH: Focal nodular
hyperplasia; HCA: Hepatocellular adenoma; HCC: Hepatocellular carcinoma;
MRI: Magnetic resonance imaging; US: Ultrasonography.
Competing interests
The authors declare that they have no competing interest.
Authors’ contribution
MH performed the statistical analysis, did the literature search, interpretated
data and drafted the manuscript. MW and IP participated in its design,
collected the data and edited the manuscript. RM and CN helped in data
acquisition, literature search and interpretation of data. PH and AS revised
the manuscript critically for important intellectual content and made
substantial contributions to data analysis. CS and PW participated in its
design, coordination and statistical analysis and helped to draft the
manuscript. All authors read and approved the final manuscript.
Author details
1Department of Radiology, University Medical Center Regensburg,
Regensburg 93042, Germany. 2Department of Radiology, University Hospital
Carl Gustav Carus Dresden, Dresden, Germany.
Received: 2 April 2013 Accepted: 26 November 2013
Published: 1 December 2013
References
1. Hagspiel KD, Neidl KF, Eichenberger AC, Weder W, Marincek B: Detection of
liver metastases: comparison of superparamagnetic iron oxide-enhanced
and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative
US, and percutaneous US. Radiology 1995, 196:471–478.
2. Kim YK, Park G, Kim CS, Yu HC, Han YM: Diagnostic efficacy of gadoxetic
acid-enhanced MRI for the detection and characterisation of liver
metastases: comparison with multidetector-row CT. Br J Radiol 2012,
85:539–547.
3. Semelka RC, Martin DR, Balci C, Lance T: Focal liver lesions: comparison of
dual-phase CT and multisequence multiplanar MR imaging including
dynamic gadolinium enhancement. J Magn Reson Imaging 2001,
13:397–401.
4. Hwang J, Kim SH, Lee MW, Lee JY: Small (</= 2 cm) hepatocellular
carcinoma in patients with chronic liver disease: comparison of
gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow
detector CT. Br J Radiol 2012, 85:e314–e322.
5. Koh DM, Brown G, Riddell AM, Scurr E, Collins DJ, Allen SD, Chau I,
Cunningham D, deSouza NM, Leach MO, Husband JE: Detection of
colorectal hepatic metastases using MnDPDP MR imaging and
diffusion-weighted imaging (DWI) alone and in combination. Eur Radiol
2008, 18:903–910.
6. Petersein J, Spinazzi A, Giovagnoni A, Soyer P, Terrier F, Lencioni R,
Bartolozzi C, Grazioli L, Chiesa A, Manfredi R, Marano P, Van Persijn Van
Meerten EL, Bloem JL, Petre C, Marchal G, Greco A, McNamara MT, Heuck A,
Reiser M, Laniado M, Claussen C, Daldrup HE, Rummeny E, Kirchin MA,
Pirovano G, Hamm B: Focal liver lesions: evaluation of the efficacy of
gadobenate dimeglumine in MR imaging–a multicenter phase III clinical
study. Radiology 2000, 215:727–736.
7. Ros PR, Freeny PC, Harms SE, Seltzer SE, Davis PL, Chan TW, Stillman AE,
Muroff LR, Runge VM, Nissenbaum MA, et al: Hepatic MR imaging with
ferumoxides: a multicenter clinical trial of the safety and efficacy in the
detection of focal hepatic lesions. Radiology 1995, 196:481–488.
8. Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, Casalino
DD, Davis PL, Francis IR, Krinsky G, Lee FT Jr, Lu D, Paulson EK, Schwartz LH,
Siegelman ES, Small WC, Weber TM, Welber A, Shamsi K: Efficacy and
safety of MR imaging with liver-specific contrast agent: U.S. multicenter
phase III study. Radiology 2005, 237:89–98.
9. Hamm B, Staks T, Muhler A, Bollow M, Taupitz M, Frenzel T, Wolf KJ,
Weinmann HJ, Lange L: Phase I clinical evaluation of Gd-EOB-DTPA as a
hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR
imaging. Radiology 1995, 195:785–792.
10. Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D: Biliary
and reticuloendothelial impairment in hepatocarcinogenesis: thediagnostic role of tissue-specific MR contrast media. Eur Radiol 2007,
17:2519–2530.
11. Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R,
Fuste LC, Heinz-Peer G, Judmaier W, Laniado M, Manfredi RM, Mathieu DG,
Muller D, Mortele K, Reimer P, Reiser MF, Robinson PJ, Shamsi K, Strotzer M,
Taupitz M, Tombach B, Valeri G, van Beers BE, Vogl TJ: Diagnostic efficacy
of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a
therapeutic strategy: comparison with intraoperative and histopathologic
findings in focal liver lesions. Eur Radiol 2008, 18:457–467.
12. Reimer P, Schneider G, Schima W: Hepatobiliary contrast agents for
contrast-enhanced MRI of the liver: properties, clinical development and
applications. Eur Radiol 2004, 14:559–578.
13. Sun HY, Lee JM, Shin CI, Lee DH, Moon SK, Kim KW, Han JK, Choi BI:
Gadoxetic acid-enhanced magnetic resonance imaging for
differentiating small hepatocellular carcinomas (< or =2 cm in diameter)
from arterial enhancing pseudolesions: special emphasis on hepatobiliary
phase imaging. Invest Radiol 2010, 45:96–103.
14. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY: Added value of
gadoxetic acid-enhanced hepatobiliary phase MR imaging in the
diagnosis of hepatocellular carcinoma. Radiology 2010, 255:459–466.
15. Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, Nakano M,
Sakamoto M, Nakazawa T, Asakawa M, Fujii H, Kitamura T, Enomoto N, Araki
T: Imaging study of early hepatocellular carcinoma: usefulness of
gadoxetic acid-enhanced MR imaging. Radiology 2011, 261:834–844.
16. Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, Choi D, Lee WJ, Lim HK: Gadoxetic
acid-enhanced MRI versus triple-phase MDCT for the preoperative
detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009,
192:1675–1681.
17. de Ledinghen V, Laharie D, Lecesne R, Le Bail B, Winnock M, Bernard PH,
Saric J, Couzigou P, Balabaud C, Bioulac-Sage P, Drouillard J: Detection of
nodules in liver cirrhosis: spiral computed tomography or magnetic
resonance imaging? A prospective study of 88 nodules in 34 patients.
Eur J Gastroenterol Hepatol 2002, 14:159–165.
18. Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, Takehara Y, Kamura T,
Gabata T, Murakami T, Ito K, Hirohashi S, Nishie A, Saito Y, Onaya H,
Kuwatsuru R, Morimoto A, Ueda K, Kurauchi M, Breuer J: Detection and
characterization of focal liver lesions: a Japanese phase III, multicenter
comparison between gadoxetic acid disodium-enhanced magnetic
resonance imaging and contrast-enhanced computed tomography
predominantly in patients with hepatocellular carcinoma and chronic
liver disease. Invest Radiol 2010, 45:133–141.
19. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO: MR imaging in patients
with suspected liver metastases: value of liver-specific contrast agent
Gd-EOB-DTPA. Magn Reson Med Sci 2007, 6:43–52.
20. Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L:
Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol
2009, 19(Suppl 5):S975–S989.
21. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D:
Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in
patients with liver cirrhosis: visualization of the biliary ducts in
comparison with patients with normal liver parenchyma. Eur Radiol
2008, 18:1577–1586.
22. Hayashida M, Ito K, Fujita T, Shimizu A, Sasaki K, Tanabe M, Matsunaga N:
Small hepatocellular carcinomas in cirrhosis: differences in contrast
enhancement effects between helical CT and MR imaging during
multiphasic dynamic imaging. Magn Reson Imaging 2008, 26:65–71.
23. van den Bos IC, Hussain SM, Dwarkasing RS, Hop WC, Zondervan PE, de
Man RA, JN IJ, Walker CW, Krestin GP: MR imaging of hepatocellular
carcinoma: relationship between lesion size and imaging findings,
including signal intensity and dynamic enhancement patterns. J Magn
Reson Imaging 2007, 26:1548–1555.
24. Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, Choi BI: Hepatocellular
carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images
and their value as an imaging biomarker. Radiology 2013, 267:776–786.
25. Akai H, Matsuda I, Kiryu S, Tajima T, Takao H, Watanabe Y, Imamura H,
Kokudo N, Akahane M, Ohtomo K: Fate of hypointense lesions on
Gd-EOB-DTPA-enhanced magnetic resonance imaging. Eur J Radiol 2012,
81:2973–2977.
26. Cherqui D, Rahmouni A, Charlotte F, Boulahdour H, Metreau JM, Meignan
M, Fagniez PL, Zafrani ES, Mathieu D, Dhumeaux D: Management of focal
nodular hyperplasia and hepatocellular adenoma in young women: a
Haimerl et al. BMC Medical Imaging 2013, 13:41 Page 8 of 8
http://www.biomedcentral.com/1471-2342/13/41series of 41 patients with clinical, radiological, and pathological
correlations. Hepatology 1995, 22:1674–1681.
27. Grazioli L, Bondioni MP, Haradome H, Motosugi U, Tinti R, Frittoli B,
Gambarini S, Donato F, Colagrande S: Hepatocellular adenoma and focal
nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in
differential diagnosis. Radiology 2012, 262:520–529.
28. Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G,
Laniado M, Manfredi RM, Mathieu DG, Mueller D, Reimer P, Robinson PJ,
Strotzer M, Taupitz M, Vogl TJ: Improved detection of focal liver lesions at
MR imaging: multicenter comparison of gadoxetic acid-enhanced MR
images with intraoperative findings. Radiology 2004, 230:266–275.
doi:10.1186/1471-2342-13-41
Cite this article as: Haimerl et al.: Added value of Gd-EOB-DTPA-
enhanced Hepatobiliary phase MR imaging in evaluation of focal solid
hepatic lesions. BMC Medical Imaging 2013 13:41.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
